Praxis Precision Medicines’ (PRAX) “Buy” Rating Reiterated at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $85.00 target price on the stock. Several other research firms have also commented on PRAX. Robert W. Baird lowered their price target on […]
Needham & Company LLC reiterated their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $85.00 target price on the stock. Several other research firms have also commented on PRAX. Robert W. Baird lowered their price target on […]
